The July issue of The Journal of Nuclear Medicine contains a study that shows the use of 177Lu-DOTA-rituximab as a radioimmunotherapy for Lymphoma patients results in a high rate of tumor response while using less radiation than current therapies. This represents a new treatment option for patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas.

The prospective study included 31 patients with histologically confirmed relapsed or refractory CD20-positive B-cell lymphoma. All patients received an initial dose of 740 MBq/m2 body surface area of 177Lu-DOTA rituximab.

To read the full report, visit http://jnm.snmjournals.org.